Physician

Paul G Welch, MD

According to 2025 Medicare claims, Paul Welch, MD (NPI: 1548259146) practices nephrology in the Hagerstown-Martinsburg, MD-WV market, with the plurality of this provider's patient population coming from Berkeley, WV. This provider's primary affiliated billing organization is OTTO ROZA M.D., P.A. (NPI: 1548256811; TIN: 520968642) and primary practice location at 25401-2977. Welch is affiliated with the ACO West Virginia (ACO ID: A3563) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Welch's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 531 traditional Medicare patients, billed 2,008 HCPCS/CPT codes, and received $220,185 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 3,507 prescription claims across 511 beneficiaries totaling $836,062 in drug costs, led by Jardiance (Empagliflozin). DME data shows 250 claims. Open Payments data shows 6 records totaling $65. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $431,594 to $220,185. In contrast, Part D prescription costs have moved sharply higher in recent years, from $233,861 to $836,062. For DME billing, this smaller-volume category changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	638	7,099	$431,594
2016	708	6,859	$406,846
2017	724	6,447	$382,358
2018	736	3,236	$376,752
2019	746	3,251	$369,865
2020	652	2,808	$340,343
2021	621	2,587	$339,122
2022	556	2,302	$274,394
2023	501	1,889	$217,452
2024	531	2,008	$220,185

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	229	1,416	$233,861
2016	251	1,562	$147,948
2017	250	1,546	$129,269
2018	255	1,442	$124,705
2019	283	1,512	$95,967
2020	300	1,571	$119,740
2021	379	2,160	$556,376
2022	378	2,621	$842,445
2023	372	2,579	$893,751
2024	511	3,507	$836,062

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	189	$11,044
2016	N/R	179	$6,668
2017	N/R	205	$6,977
2018	N/R	212	$8,481
2019	N/R	230	$6,847
2020	N/R	238	$6,421
2021	N/R	204	$3,887
2022	N/R	190	$2,960
2023	N/R	224	$3,141
2024	N/R	250	$2,726

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	71	563	$237
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	76	77	$115
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	261	373	$74
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	101	200	$53
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	90	157	$35

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	410	18,752	$345,199
Trulicity	Dulaglutide	76	2,864	$95,303
Xphozah	Tenapanor Hcl	12	690	$61,435
Velphoro	Sucroferric Oxyhydroxide	17	570	$50,847
Ozempic	Semaglutide	37	1,316	$42,467

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	63	$1,073
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	68	$803
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	76	$489
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	43	$361

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	6	$65	Fresenius USA Marketing, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Paul G. Welch, MD?

Tedicare shows public-source Medicare data for Paul G. Welch, MD (NPI 1548259146), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Paul G. Welch, MD have ACO affiliation data?

Paul G. Welch, MD is shown with ACO affiliation data for ACO West Virginia (MSSP, ACO ID A3563) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Paul G. Welch, MD?

Paul G. Welch, MD is linked to OTTO ROZA M.D., P.A. (billing NPI 1548256811) in the available physician profile data.

Does Paul G. Welch, MD have Open Payments data?

Paul G. Welch, MD has 6 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.